Press release
Lennox-Gastaut Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments
Explore Report at: www.psmarketresearch.com/market-analysis/lennox-gastaut-syndrome-therapeutics-pipeline-analysis
The growth in therapeutic pipeline of Lennox-Gastaut Syndrome can also be attributed to the upsurge in technical advancements in research, increase in funding by non-profit organization such as National Organization for Rare Disorders as well as availability of limited number of treatments.
In August 2017, INSYS Therapeutics Inc. started a Phase III study of an oral solution of cannabidiol, to assess its safety and efficacy as an adjunctive therapy for treatment in subjects with uncontrolled Lennox-Gastaut Syndrome. The trial is expected to be completed in June 2018. In December 2016, Eisai Inc. conducted a Phase III study on its drug candidate, perampanel, for reducing the drop seizures in patients with uncontrolled seizures and Lennox-Gastaut Syndrome. The trial is expected to be completed in February 2020. In January 2016, Zogenix, Inc. started a Phase II clinical study of its drug candidate, fenfluramine, in subjects having epilepsy and Lennox Gastaut Syndrome. The purpose of the study was to evaluate the anti-epileptic effects of low dose fenfluramine in these patients. The trial was expected to be completed in March 2017, however, the study is still ongoing and recruiting participants. In June 2011, Eisai Inc. strated a Phase III study of drug candidate, rufinamide, to evaluate its safety, efficacy and pharmacokinetic activity in subjects of less than four years of age and having uncontrolled Lennox-Gastaut Syndrome. The trial was completed in November 2015.
Request for Table of Content at: www.psmarketresearch.com/market-analysis/lennox-gastaut-syndrome-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of Lennox-Gastaut Syndrome therapeutics include, INSYS Therapeutics Inc., Eisai Inc., GW Research Ltd., Zogenix, Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, H. Lundbeck A/S, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Ortho-McNeil Pharmaceutical Ltd.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lennox-Gastaut Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments here
News-ID: 579107 • Views: …
More Releases from P&S Market Research - Pharmaceuticals
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of…
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis
Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where…
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the…
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
As per the findings of research, it…
More Releases for Syndrome
Hunter Syndrome Treatment Market Size, Share | Hunter Syndrome Treatment Industr …
Global Hunter Syndrome Treatment Market Report provides a detailed industry overview along with the analysis of Cost Structure, Supply Chain, Development Techniques, Retailers Analysis, Financial Support, business Strategies, Marketing Channels. Global Hunter Syndrome Treatment Market research report provides a point-by-point In-Depth analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain…
GBS GBS in Canada Guillain Barre Syndrome in Canada Guillain Barre Syndrome
What is Guillain-Barre Syndrome (GBS)?
Guillain-Barré (Ghee-yan Bah-ray) Syndrome is an intemperate disorder of the incidental nerves outside the brain and spinal cord.
GBS also called:
1. Acute Incendiary Demyelinating Polyneuropathy
2. Landry’s Ascending Paralysis
GBS is indicate by the rapid onset of numbness, weakness, and often paralysis of the legs, arms, breathing muscles, and face. Deflation is climbing meaning that…
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape.
Gorlin syndrome, also known as nevoid…
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017
ReportsWeb.com published “Gorlin Syndrome Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Original Content:
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape.
Gorlin…
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syn …
Global Markets Directs, Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and…
Complex Regional Pain Syndrome
“Complex Regional Pain Syndrome Global 2016 Clinical Trials Review, H2" provides an detailed overview of Complex Regional Pain Syndrome scenario.
Report includes top line data relating on Complex Regional Pain Syndrome Global clinical trials scenario.
This report on Complex Regional Pain Syndrome also includes an review of trial numbers as well as their ( Complex Regional Pain Syndrome ) average enrollment in uppermost/top countries which are conducted worldwide.
Complex Regional…
